Havn Life is one of a select number of companies that are included in the new ETF
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF will begin trading on the Neo Exchange on January 26, 2021.
The ETF will invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.
Havn Life is one of seventeen companies that met the requirements of listing within the ETF. The ETF is managed by Horizons ETF Management, one the largest ETF providers in Canada, with over CDN $16 billion in assets under management across 93 ETFs. Horizons also brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries. Inclusion into an ETF is an important milestone for Havn Life’s investors and stakeholders. The ETF will bring additional exposure to potential new investors and generate value for existing shareholders.
Tim Moore remarked, “Our team is excited to be included in Horizons Psychedelics ETF, which will allow Havn Life to become visible to and available to a wider investment community. This is an opportunity to provide added shareholder value as we continue to execute our operational milestones.”
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.